Latest news with #SIGNASprint
Business Insider
29-05-2025
- Business
- Business Insider
GE HealthCare unveils gradient 1.5T MRI system
GE HealthCare (GEHC) unveiled SIGNA Sprint, an FDA 510(k) pending ultra-premium wide bore 1.5T high-performance gradient MRI system, at the International Society for Magnetic Resonance in Medicine 2025. This technology is designed to unlock advanced imaging possibilities in cardiology, oncology and other clinical and research areas. Protect Your Portfolio Against Market Uncertainty
Yahoo
13-05-2025
- Business
- Yahoo
GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech
GE HealthCare Technologies Inc. GEHC recently introduced SIGNA Sprint, a next-generation ultra-premium 1.5T MRI system at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025, engineered to push the boundaries of traditional MRI performance. With a 65/200 per-axis gradient strength and built-in AI tools, SIGNA Sprint delivers sharp imaging for cardiology and oncology, enabling faster, more accurate diagnostics. As healthcare providers increasingly prioritize imaging solutions that balance diagnostic power, cost-effectiveness and patient comfort, SIGNA Sprint stands out with its blend of cutting-edge performance and accessibility. Built-in AI technologies streamline workflows while its patient-centric design, including free-breathing capability and AIR Coils, enhances the overall imaging experience. With SIGNA Sprint, GE HealthCare aims to redefine what's possible at 1.5T, expanding clinical capabilities without the added infrastructure demands of higher-field MRI systems. Shares of the company moved north 6.1% and closed at $74.11 on Monday following the announcement, primarily due to the U.S.-China trade deal. In the year-to-date period, GEHC shares have lost 5.3% against the industry's 5.3% growth. The S&P 500 decreased 4.5% in the same time frame. The launch of SIGNA Sprint positions GE HealthCare to strengthen its premium MRI market presence with a cost-effective, high-performance alternative to 3.0T systems. Its AI-driven capabilities and enhanced diagnostic features make it appealing to hospitals and research institutions, driving adoption and recurring service revenue. This innovation could support sustained revenue growth, improve investor confidence, and enhance long-term stock performance. Meanwhile, GEHC currently has a market capitalization of $31.99 billion. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%. Image Source: Zacks Investment Research SIGNA Sprint is an ultra-premium, wide-bore MRI system designed to deliver imaging power typically found in 3.0T systems on the more accessible 1.5T platform. A FDA 510(k) application is pending for the system, and clearance is expected to expand GEHC's diagnostic capabilities in cardiology, oncology, and other advanced clinical and research domains. It delivers exceptional diffusion imaging, vital for oncology, and enables crystal-clear visualization of sub-millimetric structures critical in precision care. SIGNA Sprint's core advantage lies in its integrated AI technologies, AIR Recon DL, Sonic DL, and AIR x, which enhance image reconstruction, accelerate scan times, and improve diagnostic accuracy. These deep learning tools enable quantitative MRI, offering deeper insights into tissue characteristics, particularly in cardiac imaging, while streamlining workflows and enhancing treatment monitoring. Designed for patient comfort with a 70cm wide bore, free-breathing capabilities, and AIR Coils, SIGNA Sprint combines advanced imaging power with improved patient experience. As demand for scalable MRI solutions rises, particularly in cardiology and oncology, SIGNA Sprint offers a cost-effective, AI-powered system poised to drive both clinical impact and commercial success for GE HealthCare. At ISMRM 2025, GE HealthCare is expected to showcase its latest MRI innovations, including SIGNA Sprint, which features SIGNA MAGNUS— a high-resolution head-only scanner with advanced gradients. Additionally, Sonic DL 3D, a deep learning-based MRI acceleration technology, and Freelium, a helium-free sealed magnet platform in development to reduce helium reliance, are also expected to be showcased. These advancements highlight GE HealthCare's leadership in MRI technology. In recent months, GEHC has made strategic moves to expand its imaging services and AI capabilities. In March, GEHC unveiled Freelium, a next-generation sealed magnet platform at ECR 2025, designed to revolutionize Magnetic Resonance imaging. The platform uses less than 1% of helium compared to traditional systems, promoting sustainability and expanding access to quality imaging in helium-scarce regions. In January, GEHC partnered with Sutter Health to form a seven-year Care Alliance, enhancing access to innovative imaging services and improving the patient and clinician experience across the Sutter Health network. This collaboration aims to create a more seamless and coordinated healthcare system. GEHC carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. CVS Health has a long-term estimated growth rate of 11.4%. CVS's earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 13.3%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
GE HealthCare unveils ultra-premium, high-performance gradient 1.5T MRI system
SIGNA™ Sprint, a new wide bore 1.5T MRI scanner, is designed to provide power previously unattainable at 1.5T, for clarity in cardiology and oncology imaging Advanced high-performance gradient technology leverages built-in AI solutions designed to enable clear, fast imaging for improved workflow HONOLULU, May 12, 2025--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today unveiled SIGNA™ Sprint, an FDA 510(k) pending1 ultra-premium wide bore 1.5T high-performance gradient MRI system, at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025. This innovative technology is designed to unlock advanced imaging possibilities in cardiology, oncology and other clinical and research areas. The need for advanced diagnostics in cardiology and oncology continues to grow, with cardiovascular disease accounting for 32% of global deaths,2 and cancer accounting for nearly 10 million deaths per year.3 Meeting this demand with advanced MRI technologies has the potential to make significant impact for cardiology and oncology patients. With the goal of delivering higher gradient benefits previously attainable on only 3.0T systems, SIGNA Sprint is designed to offer high-performance scanning made simple at 1.5T, with exceptional diffusion imaging, a critical tool in oncology diagnosis and treatment planning. SIGNA Sprint is also designed to equip clinicians and researchers with the ability to expand the current 1.5T boundaries, aiming to enable fast clinical translation and pioneering research. SIGNA Sprint, with a high-gradient performance of 65/200 per axis for fast imaging and exceptional image quality, is designed to deliver crystal-clear visualization of sub-millimetric structures and deep learning solutions to support diagnostics and treatment response monitoring in oncology patients. This new system supports clinicians' shift to quantitative MRI and a deeper understanding of tissue characteristics, going beyond basic assessment of anatomy. The adoption of deep-learning reconstruction techniques for accelerated cardiac MRI aims to reduce the time and expertise needed to interpret scans and drive consistency and reliability. "We are driven to push the boundaries of what's possible in MRI with our ultra-premium segment, as our goal is to set a new standard in diagnostic research and precision care that allows for earlier clinical detection and treatment response," said Kelly Londy, CEO, MR, GE HealthCare. "We are working to enhance diagnostic capabilities to provide highly accurate imaging with peace of mind for patients. We hope to help clinicians unlock new horizons for research in advanced imaging." SIGNA Sprint also is designed to optimize patient comfort, providing a 70cm wide bore space, free-breathing capabilities, and blanket-like AIR ™ Coils to improve the patient experience. This next-generation, high-performance platform is designed to benefit from built-in AI technologies – AIR™ Recon DL, Sonic DL™ and AIR x™ – which enable high-quality imaging even in the most demanding anatomies. SIGNA Sprint aims to support clinician goals of providing precision care through the entire care pathway, from the early diagnostic stage to treatment monitoring. Latest in MRI advancements to be showcased at ISMRM GE HealthCare also will showcase the latest advancements in MRI technologies at ISMRM, including: SIGNA™ MAGNUS: A head-only MR scanner designed to support high resolution, high signal-to-noise ratio, diffusion-weighted imaging, and short scan times. GE HealthCare has demonstrated leadership in high-performance gradient technology with the introduction of HyperG gradients, one of the most efficient gradient coils on the market4. Sonic DL™ 3D: Designed to accelerate MRI scans across a wide range of clinical applications, Sonic DL for 3D5 builds on GE HealthCare's deep learning innovation legacy and the success of AIR Recon DL, which has helped more than 50 million patients to date. Freelium™: a helium-free sealed6 magnet platform in development, aims to dramatically reduce liquid helium usage without sacrificing power efficiency, operational security and clinical performance. Learn more about SIGNA Sprint and other GE HealthCare MRI technologies at the International Society for Magnetic Resonance in Medicine through May 15, in Honolulu, Hawaii, or visit online at About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. 1 SIGNA™ Sprint is 510(k) pending at US FDA. Not yet CE marked. Not available for sale in any region. 2 World Health Organization(2025). CVDs statistics and treatment. World Health Organization. Retrieved from 3 World Health Organization. (2025). Cancer statistics and treatment. World Health Organization. Retrieved from 4 SIGNA™ MAGNUS is 510(k) cleared with the FDA. Not CE Marked. Not available for sale in all regions. GE HealthCare data on file. 5 Sonic DL for 3D is 510(k) pending at the US FDA. Not yet CE Marked. Not available for sale in all regions. 6 Helium-free: Helium is permanently enclosed in the magnet. Technology in development that represents ongoing research and development efforts. Not for sale. Not CE marked. Not cleared or approved by the US FDA or any other global regulator for commercial availability. View source version on Contacts GE HealthCare Media Contact: Katie ScrivanoM +1 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
12-05-2025
- Business
- Business Wire
GE HealthCare unveils ultra-premium, high-performance gradient 1.5T MRI system
HONOLULU--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today unveiled SIGNA™ Sprint, an FDA 510(k) pending 1 ultra-premium wide bore 1.5T high-performance gradient MRI system, at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025. This innovative technology is designed to unlock advanced imaging possibilities in cardiology, oncology and other clinical and research areas. The need for advanced diagnostics in cardiology and oncology continues to grow, with cardiovascular disease accounting for 32% of global deaths, 2 and cancer accounting for nearly 10 million deaths per year. 3 Meeting this demand with advanced MRI technologies has the potential to make significant impact for cardiology and oncology patients. With the goal of delivering higher gradient benefits previously attainable on only 3.0T systems, SIGNA Sprint is designed to offer high-performance scanning made simple at 1.5T, with exceptional diffusion imaging, a critical tool in oncology diagnosis and treatment planning. SIGNA Sprint is also designed to equip clinicians and researchers with the ability to expand the current 1.5T boundaries, aiming to enable fast clinical translation and pioneering research. SIGNA Sprint, with a high-gradient performance of 65/200 per axis for fast imaging and exceptional image quality, is designed to deliver crystal-clear visualization of sub-millimetric structures and deep learning solutions to support diagnostics and treatment response monitoring in oncology patients. This new system supports clinicians' shift to quantitative MRI and a deeper understanding of tissue characteristics, going beyond basic assessment of anatomy. The adoption of deep-learning reconstruction techniques for accelerated cardiac MRI aims to reduce the time and expertise needed to interpret scans and drive consistency and reliability. 'We are driven to push the boundaries of what's possible in MRI with our ultra-premium segment, as our goal is to set a new standard in diagnostic research and precision care that allows for earlier clinical detection and treatment response,' said Kelly Londy, CEO, MR, GE HealthCare. 'We are working to enhance diagnostic capabilities to provide highly accurate imaging with peace of mind for patients. We hope to help clinicians unlock new horizons for research in advanced imaging.' SIGNA Sprint also is designed to optimize patient comfort, providing a 70cm wide bore space, free-breathing capabilities, and blanket-like AIR ™ Coils to improve the patient experience. This next-generation, high-performance platform is designed to benefit from built-in AI technologies – AIR™ Recon DL, Sonic DL™ and AIR x™ – which enable high-quality imaging even in the most demanding anatomies. SIGNA Sprint aims to support clinician goals of providing precision care through the entire care pathway, from the early diagnostic stage to treatment monitoring. Latest in MRI advancements to be showcased at ISMRM GE HealthCare also will showcase the latest advancements in MRI technologies at ISMRM, including: SIGNA™ MAGNUS: A head-only MR scanner designed to support high resolution, high signal-to-noise ratio, diffusion-weighted imaging, and short scan times. GE HealthCare has demonstrated leadership in high-performance gradient technology with the introduction of HyperG gradients, one of the most efficient gradient coils on the market 4. Sonic DL™ 3D: Designed to accelerate MRI scans across a wide range of clinical applications, Sonic DL for 3D 5 builds on GE HealthCare's deep learning innovation legacy and the success of AIR Recon DL, which has helped more than 50 million patients to date. Freelium™: a helium-free sealed 6 magnet platform in development, aims to dramatically reduce liquid helium usage without sacrificing power efficiency, operational security and clinical performance. Learn more about SIGNA Sprint and other GE HealthCare MRI technologies at the International Society for Magnetic Resonance in Medicine through May 15, in Honolulu, Hawaii, or visit online at About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. 1 SIGNA™ Sprint is 510(k) pending at US FDA. Not yet CE marked. Not available for sale in any region. 2 World Health Organization(2025). CVDs statistics and treatment. World Health Organization. Retrieved from 3 World Health Organization. (2025). Cancer statistics and treatment. World Health Organization. Retrieved from 4 SIGNA™ MAGNUS is 510(k) cleared with the FDA. Not CE Marked. Not available for sale in all regions. GE HealthCare data on file. 5 Sonic DL for 3D is 510(k) pending at the US FDA. Not yet CE Marked. Not available for sale in all regions. 6 Helium-free: Helium is permanently enclosed in the magnet. Technology in development that represents ongoing research and development efforts. Not for sale. Not CE marked. Not cleared or approved by the US FDA or any other global regulator for commercial availability.
